Skip to main content
. Author manuscript; available in PMC: 2014 Apr 16.
Published in final edited form as: Auton Neurosci. 2013 Aug 20;177(2):291–296. doi: 10.1016/j.autneu.2013.08.064

Table 2.

Risk of non-persistence on treatments for orthostatic hypotension

Risk of Discontinuation or Change in Treatmet
Treatment Number of episodes of use Number of events Median duration on treatment (IQR) Unadjusted Hazard Ratio (95% confidence interval) Adjusted Hazard Ratio (95% confidence interval)
Fludrocortisone 1103 329 254 (119–783) Reference Reference
Midodrine 664 210 259 (119–807) 1.04 (0.89, 1.24) 1.07 (0.90, 1.28)
Risk of Discontinuation
Fludrocortisone 1103 298 268 (119, 816) Reference Reference
Midodrine 664 169 304 (133, 865) 0.93 (0.77, 1.11) 0.97 (0.80, 1.18)